HC Wainwright Reaffirms “Buy” Rating for RAPT Therapeutics (NASDAQ:RAPT)

HC Wainwright restated their buy rating on shares of RAPT Therapeutics (NASDAQ:RAPT) in a report published on Monday morning,Benzinga reports. HC Wainwright currently has a $10.00 target price on the stock. HC Wainwright also issued estimates for RAPT Therapeutics’ Q1 2025 earnings at ($0.16) EPS, Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($0.76) EPS and FY2026 earnings at ($0.91) EPS.

Other research analysts have also recently issued research reports about the stock. Stifel Nicolaus reiterated a “hold” rating and issued a $2.00 target price (down previously from $7.00) on shares of RAPT Therapeutics in a research note on Wednesday, November 13th. Piper Sandler cut shares of RAPT Therapeutics from an “overweight” rating to a “neutral” rating and cut their target price for the company from $8.00 to $2.00 in a research note on Monday, November 11th. JPMorgan Chase & Co. cut shares of RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Monday, November 11th. Finally, Wells Fargo & Company cut their target price on shares of RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating for the company in a research note on Tuesday, November 12th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $5.29.

RAPT Therapeutics Stock Up 9.6 %

Shares of RAPT opened at $1.25 on Monday. RAPT Therapeutics has a 12 month low of $0.79 and a 12 month high of $9.65. The company has a 50-day moving average price of $1.22 and a two-hundred day moving average price of $1.53. The stock has a market cap of $43.70 million, a price-to-earnings ratio of -0.45 and a beta of -0.31.

RAPT Therapeutics (NASDAQ:RAPT) last posted its earnings results on Thursday, March 6th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.69). Equities research analysts expect that RAPT Therapeutics will post -2.14 EPS for the current fiscal year.

Institutional Trading of RAPT Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of RAPT. Picton Mahoney Asset Management grew its holdings in RAPT Therapeutics by 994.4% during the 4th quarter. Picton Mahoney Asset Management now owns 16,175 shares of the company’s stock worth $26,000 after acquiring an additional 14,697 shares during the period. JPMorgan Chase & Co. grew its holdings in RAPT Therapeutics by 298.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company’s stock worth $34,000 after acquiring an additional 25,130 shares during the period. Readystate Asset Management LP acquired a new stake in RAPT Therapeutics during the 3rd quarter worth $36,000. Barclays PLC grew its holdings in RAPT Therapeutics by 277.2% during the 3rd quarter. Barclays PLC now owns 39,729 shares of the company’s stock worth $79,000 after acquiring an additional 29,195 shares during the period. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in RAPT Therapeutics during the 4th quarter worth $63,000. Institutional investors and hedge funds own 99.09% of the company’s stock.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.